1. Introduction {#sec1}
===============

Viral hepatitis is a major health problem in all parts of world. HBV and HCV are hepatotropic viruses leading to significant morbidity and mortality worldwide \[[@B1], [@B2]\]. HBV is a member of Hepadnaviridae family harboring a DNA genome while HCV is RNA virus that belongs to Flaviviridae family \[[@B3]\].

Hepatitis B and C are transmitted parentally mainly as a result of blood contact, including injury with contaminated instruments and sharing of needles, or by sexual contact and also through parental transmission from mother to child \[[@B4]\]. Hepatitis B and C infections can lead to an acute or silent course of liver disease progressing from liver impairment to liver failure, cirrhosis of liver, and hepatocellular carcinoma \[[@B1], [@B2]\].

The global prevalence of HCV is about 2.8%; while more than 185 million people are infected with HCV alone, HBV prevalence is variable around the globe; however, among the 2 billion people infected with HBV, about 360 million people are chronic carriers around the world \[[@B2], [@B5]\]. South and Southeast Asian countries have estimated prevalence rate from 1.5 to 3.5% \[[@B2]\]. In Pakistan the seroprevalence of hepatitis B surface antigen (HBsAg) and HCV antibodies is about 2.5% and 4.8%, respectively, with an overall infection rate of 7.6% in the general population \[[@B6]\].

HBV and HCV may appear as coinfection due to the same mode of transmission \[[@B4], [@B7]\]. Several studies documented that HBV and HCV coinfection accelerates liver disease progression and increases the risk of hepatocellular carcinoma \[[@B7]--[@B9]\], and the patients need high dose of interferon treatment \[[@B10]\]. Although a growing body of the literature is available on the prevalence of HCV and HBV \[[@B6], [@B11], [@B12]\], limited data is documented on the coinfection of HBV and HCV from Islamabad.

The present study reported the seroprevalence and coinfection of HBV and HCV among patients seeking hospital care in Islamabad. Findings from this study may be helpful to formulate strategy for the prevention of HBV and HCV coinfection.

2. Materials and Methods {#sec2}
========================

2.1. Study Area {#sec2.1}
---------------

The study was conducted from 1st July to 31st August, 2011, at Pakistan Institute of Medical Sciences (PIMS), Islamabad. All the patient seeking hospital care were enrolled in the study.

2.2. Sample Collection {#sec2.2}
----------------------

During this period a total of 845 blood samples from patients seeking hospital care suspected for viral hepatitis were collected in sterilized vacutainer, dully labeled with sex, age, areas, and date of collection, and kept in refrigerator at −20°C for further process.

2.3. Sample Screening {#sec2.3}
---------------------

A total of 845 blood samples were screened for detection of HBV and HCV using ICT (immunochromatography test). The screen samples were further subjected to ELISA for reconfirmation of the test.

2.4. Enzyme Linked Immunosorbent Assay (ELISA) {#sec2.4}
----------------------------------------------

For detection of HBsAg and HCV antibodies two types of ELISA kits were used. HbsAg ELISA kit is an enzyme-linked immunosorbent assay (ELISA) for qualitative detection of HBsAg in human serum or plasma. For detection of HBsAg with ELISA kit, sandwich ELISA method was used. HCV ELISA kit is an enzyme-linked immunosorbent assay for qualitative detection of antibodies to hepatitis C virus in human serum or plasma. For HCV antibody detection indirect ELISA was employed. The Biokit ELISA system (BEST 2000) was used for running ELISA.

2.5. Data Analysis {#sec2.5}
------------------

The data was analyzed with Window 7, Microsoft Excel 2007 (Microsoft, USA).

3. Results and Discussion {#sec3}
=========================

Of total 845 collected samples, 255 (30.1%) samples were positive for hepatitis B and C. Out of 255 samples, 45 (5.3%) were positive for HBsAg while 199 (23.5%) were positive for anti-HCV. Among 255, 11 (1.3%) were seropositive for both HBsAg and anti-HCV (coinfection) ([Table 1](#tab1){ref-type="table"}). Among the seropositive male (*n* = 122, 47.8%), HBV was more prevalent (*n* = 29, 23.8%) while female patients (*n* = 112, 84.2%) had a high frequency of HCV (*n* = 133, 52.2%). The coinfection rate was higher in male individuals (*n* = 06, 4.9%) as compared to female patients (*n* = 05, 3.8%) ([Table 2](#tab2){ref-type="table"}). Among the age group variable HBV, HCV, and coinfection were found to be more frequent in the age groups of 21--30 (*n* = 74, 29%) and 30--40 (*n* = 63, 24%) years while age groups of 1--9 (*n* = 04, 02%) and 70--80 (*n* = 04, 02%) years are less infected by HBV and HCV ([Table 3](#tab3){ref-type="table"}). The seropositivity for HBsAg was higher in unmarried individuals (*n* = 25, 31.2%) while anti-HCV was more prevalent in married individuals (*n* = 147, 84%) ([Table 4](#tab4){ref-type="table"}). Moreover, samples collected from General (*n* = 87, 34.1%) and Gastroenterology 54 (21.1) ward showed increased HCV and HBV infection rates. The samples collected from Pulmonology ward showed less seropositivity for HBV and HCV (*n* = 03, 1.1%) markers ([Table 5](#tab5){ref-type="table"}). Viral hepatitis is a major health problem worldwide. HBV and HCV are becoming endemic for the entire world. HBV and HCV cause coinfection due to the same transmission mode \[[@B4], [@B7]\]. Investigating the coinfection HBV and HCV is crucial as it may accelerate the course of the liver damage, increase the risk of hepatocellular carcinoma, and affect therapeutic response to antiviral molecules \[[@B7]--[@B10]\].

In the present study, a total of 845 hospitalized and nonhospitalized suspected viral hepatitis patients were screened for the serodetection of HBV and HCV infection. It was observed that anti-HCV positivity was much higher (23.5%) compared to HBsAg (5.3%). Another study from Rawalpindi reported HBsAg prevalence (2.7%) and HCV positivity (10.4%). These contradictions may exist due to the study on general population and also immunochromatographic techniques (ICT) used for anti-HCV detection by Gul et al. \[[@B13]\]; while in the present study we target hospitalized and nonhospitalized patients, ELISA was used for the detection HCV antibodies.

The observed coinfection rate of HBV and HCV was 1.30%, which is in line with a previous study conducted by Raja et al. which reported the overall coinfection rate of about 1.1% in viral hepatitis suspected patients referred by different hospitals and clinics \[[@B12]\]. The rate of HBV was more in male patients as compared with female patients which is already reported by Qureshi et al. \[[@B6]\]. This might be the different immune response evoked in both male and female patients. In this study age groups of 21--30 and 40--50 years showed highest frequency of HBV and HCV related hepatitis. Other studies also documented high prevalence in age group of 22--30 and age group above 40 \[[@B13]--[@B15]\]. The possible explanation might be the increased chances of infection in the mentioned age groups. It was observed that HBV was more prevalent in unmarried patients, as HBV can be transmitted through sexual contact \[[@B16]\], and thus these patients are free to indulge in more sexual activity. In case of HCV, married patients were more prone to infection which is in line with a previous study \[[@B17]\]. Furthermore, samples collected form General and Gastroenterology ward showed increased HCV and HBV infection rate.

4. Conclusions {#sec4}
==============

It was concluded from the study that prevalence of HCV and HBV in Pakistan is at an increasing rate. Large-scale studies are needed to understand the epidemiology of HCV and HBV infections. The data of the current study will help in the effective prevention and control measures against HBV and HCV infection.
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###### 

Incidence of HBV, HCV, and coinfection. *N* = 845.

  Serological markers      Seroprevalence
  ------------------------ ----------------
  HBsAg                    45 (5.3)
  Anti-HCV                 199 (23.5)
  Coinfection              11 (1.30)
                           
  Overall seropositivity   255 (30.1)

###### 

Gender-wise seropositivity of hepatitis B, C, and coinfection. *n* = 845.

  ---------------------------------------------------------------------
  Serological markers   Gender       Total prevalence\   
                                     *n* (%)             
  --------------------- ------------ ------------------- --------------
  HBsAg                 29 (23.8)    16 (12)             45 (5.32%)

  Anti-HCV              87 (71.3)    112 (84.2)          199 (23.55%)

  Coinfection           06 (4.9)     05 (3.8)            11 (1.3%)

                                                         

  Total                 122 (47.8)   133 (52.2)          255 (30.1%)
  ---------------------------------------------------------------------

###### 

Seropositivity of HBsAg, anti-HCV, and coinfection in different age groups.

  Age groups   HBsAg   Anti-HCV   Coinfection   Total
  ------------ ------- ---------- ------------- ----------------
  1--9         01      03         00            04 (0.47%)
  10--20       07      11         01            19 (2.24%)
  21--30       18      53         03            74 (8.75%)^♠^
  30--40       09      52         02            63 (7.45%)^♠^
  41--50       08      40         03            51 (6.03%)^♠^
  51--60       03      20         01            24 (2.84%)
  61--70       00      15         01            16 (1.8%)
  71--80       00      03         01            04 (0.47%)
                                                
  Total        46      197        12            255 (30.1%)^♠^

^♠^Statistical analysis; univariate ANOVA. Significant (*P* \< 0.05).

###### 

Seropositivity of viral hepatitis in different marital status patients. *n* = 845.

  ---------------------------------------------------------------
  Serological markers   Married      Unmarried   Total\
                                                 *n* (%)
  --------------------- ------------ ----------- ----------------
  HBsAg                 21 (12)      25 (31.2)   46 (5.68%)^♠^

  Anti-HCV              147 (84)     50 (62.5)   197 (23.3%)^♠^

  Coinfection           07 (4)       05 (6.2)    12 (1.42%)

                                                 

  Total                 175 (68.6)   80 (31.3)   255 (30.1%)^♠^
  ---------------------------------------------------------------

^♠^Statistical analysis; univariate ANOVA. Significant (*P* \< 0.05).

###### 

Seropositivity of hepatitis B, C, and coinfection in patients from different hospital wards and departments *n* = 845.

  Departments        HBsAg   Anti-HCV   Coinfection   Total
  ------------------ ------- ---------- ------------- ----------------
  General ward       15      70         02            87 (10.2%)^♠^
  Gastroenterology   10      41         03            54 (6.39%)^♠^
  General medicine   07      33         00            40 (4.73%)^♠^
  Emergency          08      12         00            20 (2.36%)^♠^
  Cardiology         02      08         00            10 (1.18%)
  Nephrology         00      08         02 (18)       10 (1.18%)
  Dental OPD         00      05         01 (9)        06 (0.71%)
  Urology            00      05         00            05 (0.59%)
  Ophthalmology      00      04         01 (9)        05 (0.59%)
  Pulmonology        01      02         00            03 (0.35%)
  Surgical ward      02      07         01 (9)        10 (1.18%)
  Psychiatry         00      05         00            05 (0.59%)
                                                      
  Total              45      199        11            255 (30.1%)^♠^

^♠^Statistical analysis; univariate ANOVA, Duncan test. Significant (*P* \< 0.05).
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